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BACKGROUND
Following discussions at the UKCCCR Trials Committee in 1995,
a decision was taken during early 1996 to set up a Working Group
to consider the management of elderly cancer patients and their
entry into clinical trials. This decision was subsequently endorsed
by the Main Committee of the UKCCCR. Dr Peter Harper (Guy’s
Hospital, London) kindly agreed to chair the Group and the other
members were then recruited (see below). The Group met for the
first time in July 1996 and on five further occasions up until
October 1997. This short paper summarizes the proceedings to
date.
TERMS OF REFERENCE
The following Terms of Reference for the Group were drawn up
by Dr Peter Twentyman (Executive Secretary, UKCCCR) and
Professor Nick Thatcher (Chairman, UKCCCR Trials
Committee). These were agreed and adopted by the first meeting
of the Group.
To advise the UKCCCR upon:
a. why relatively few elderly patients are entered into cancer
clinical trials and whether any action could help the situation.
b. whether research (including clinical trials) specifically aimed
at treatment of elderly patients is needed.
c. any other related questions which the Working Group consider
appropriate.
THE PROBLEM
Cancer is predominantly a disease of the elderly. With the current
trend in the UK towards an ageing population, treatment of cancer
in the elderly will become a greater problem. By 1996, 91% of
male and 89% of female deaths from malignant neoplasia occurred
in the 55+ age group, whilst 42% and 48% respectively were
deaths in men and women aged 75 and over (Office of National
Statistics, 1997). Randomized controlled clinical trials are
currently considered the ‘gold standard’ for the development of
new treatments for cancer. However, there is evidence that
relatively few elderly patients are entered into such trials (Tremble
et al, 1994). In a recent South West Oncology Group Study in the
USA, it was found that the elderly represented only 25% of the
15 500 total participants despite comprising 63% of the cancer
patients population (Unger et al, 1998). Hence, elderly patients are
deprived of the potential benefit of ‘state of the art’ treatments and
the age-spectrum upon which a new treatment is tested does not
reflect that of the general population of patients who will receive
the new treatment if it becomes standard. In the USA, positive
initiatives to address these issues have been taken (Castellucci,
1999).
There is substantial evidence to indicate that, with a range of
tumour types, given similar treatments, elderly patients have a
relative survival similar to that of younger patients (Begg and
Carbone, 1983; Dhodapkar et al, 1996; Siu et al, 1996). However,
a number of studies have shown that elderly patients often have
more advanced tumours at the time of diagnosis (Bergman et al,
1992; Busch et al, 1996; Goodwin et al, 1996) and receive less
aggressive treatment (Newcomb and Carbone, 1993; August et al,
1994; Higtower et al, 1994; McKenna, 1994; Newschaffer et al,
1996) than their younger counterparts. Although most of these
reports emanate from North America, it seems likely that a similar
situation exists in the UK. Certainly a number of organizations in
the UK (e.g. Age Concern England) are concerned that elderly
patients frequently receive inadequate treatment. It is worth noting
that the Health of the Nation mortality target for breast cancer
refers only to ‘the population invited for screening’ (i.e. those
under 65) (Department of Health, 1995) and it is likely that newer
targets will also exclude older women.
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Membership
The present membership of the Group is as follows:
Dr Peter Blake The Royal Marsden Hospital, London
Professor J Grimley Evans The Radcliffe Infirmary, Oxford
Professor Lesley Fallowfield CRC Psychosocial Oncology Group, UCLMS
Professor Ian Fentiman Guy’s Hospital, London
Dr Margot Gosney Royal Liverpool Hospital, Liverpool
Dr Emily Grundy Centre for Population Studies, London School of Hygiene & Tropical Medicine
Dr Peter Harper Guy’s Hospital, London (Chairman)
Ms Hazel Heath Chair, RCN Forum for Nurses Working with Older People
Dr Iona Heath The Kentish Town Health Centre, London
Professor Kay-Tee Khaw Addenbrooke’s Hospital, Cambridge
Mr John Northover St Mark’s Hospital, Middlesex
Ms Gill Oliver Clatterbridge Centre for Oncology, The Wirral
Ms Val Speechley Royal Marsden Hospital, London
Dr Peter Twentyman UKCCCR, London (Secretary)
Ms Jane Whelan Age Concern England, LondonREPRESENTATION OF ELDERLY PATIENTS IN
TRIALS
Clearly there are different opinions as to the age at which a patient
can reasonably be regarded as ‘elderly’. For the present purposes,
however, a cut-off at 65 appears to be an acceptable working basis.
In the past, many cancer clinical trials have specifically listed
age limits within the inclusion/exclusion criteria. The practice has,
however, recently become much less common. Whilst it is widely
believed that elderly patients are currently under-represented in
trials without such obvious age limits, there do not appear to be
any UK data available to substantiate this belief. In general, UK
Cancer Registries do not include, within their standard data set,
whether or not patients are entered into trials (personal communi-
cation to P Twentyman). However, the Thames Cancer Registry
are intending to include this information in future (personal
communication to P Twentyman). Information regarding the age
distribution of patients being diagnosed or dying of specific cancer
types is available from cancer registries. Furthermore, data are
stored by individual cancer trials offices regarding the age distri-
bution of patients being entered into trials. Hence comparison of
such data sets may potentially give an appropriate guide to the
extent of the problem. A more definitive approach, however,
would require the collation and comparison of data sets based on
the same population. This would be a quite difficult exercise
which would need specific funding as a research exercise to be
carried out jointly by cancer registry/trials office personnel.
REASONS FOR POOR ENTRY
Within the Group, it is believed that a number of possible reasons
could explain the poor representation of elderly patients in trials.
These could include:
a.Previous explicit upper age limits
b.Late presentation by patient
c.GP’s decision not to refer the patient for active therapy
d.Consultant’s decision not to offer active therapy
e.Consultant’s decision not to offer trial entry
f.Patient’s refusal to accept randomization.
A definitive study of the relative importance of these reasons can
probably not be based on self-completion questionnaires sent to
patients, GPs or consultants. These would be likely to have a low
rate of return and be regarded as over-simplistic. Similarly,
examination of hospital notes or other records is unlikely to be
particularly helpful on its own. A worthwhile study would require
structured interviews with patients/doctors, carried out by experts
in qualitative psychosocial research (Meredith, 1996). This would
require significant funding.
There is belief within the Group that elderly patients often have
different expectations of doctors than younger patients and were
much more likely to rely unquestioningly on the doctor’s opinion
rather than making their own decision. It is a matter of continuing
debate as to whether a patient who clearly states (in an ethical and
non-persuasive situation) a wish that the doctor makes all the
decisions can be regarded as having given informed consent to
trial entry (Tobias, 1997).
It remains, of course, unproven that under-representation of
elderly patients into trials has, in itself, a detrimental effect on their
treatment. However, in the light of evidence that, in general,
patients entered into clinical trials (even those in control arms) do
better than patients not entering trials (Davis et al, 1985;
Karjalainen and Palva, 1989), this would seem very likely to be
the case. More generally, under-representation in trials is likely to
be detrimental to the development of optimal care for older
patients as a group.
SPECIFIC PROBLEM — TOXICITY OF
TREATMENT
The Group considered the general question of whether the toxicity
of treatment was likely to be greater in elderly patients. There was
no strong feeling that this was the case, and certainly, the
published evidence does not generally support this view (Begg and
Carbone, 1983; Giovanazzi-Baannon et al, 1994; Monfardini et al,
1995). Indeed some of the newer chemotherapuetic agents appear
to have a particular beneficial therapeutic index in elderly patients
(Lichtman, 1998). However, co-morbidity can prevent the admini-
stration of some potentially beneficial interventions (Satariano,
1993; Newschaffer et al, 1996). It was agreed that some clinicians
may be reluctant to enter elderly patients as they felt that failure to
complete the prescribed treatment without dose reduction was
more likely in such patients. The Group took the view, however,
that trial protocols should usually include provision for dose
reduction in a way which did not bias entry against patients for
whom dose reduction was perceived as more likely.
SPECIFIC PROBLEM — QUALITY OF LIFE DATA
Quality of life measures are now an important aspect of clinical
trials of new cancer therapies. There is evidence that elderly
people may rate their quality of life more highly than the proxy
assessments made of them by their carers (Baur and Okun, 1983;
Ganz, 1993) and, also, that they regard quality of life issues as a
higher priority in clinical decision-making than younger patients
(McKenna, 1994; Yellen et al, 1994). Furthermore, elderly
patients’ quality of life scores may be superior to those found in
younger people (Yellen et al, 1994). There are several reasons for
these findings including the fact that elderly patients may indeed
be less functionally and psychologically impaired than stereo-
typical expectations would suggest (Yellen et al, 1994). Elderly
people may also make comparative judgements, rating themselves
as performing well ‘for someone of my age and stage’ (Grimley
Evans, 1992). Quality of life assessment in older people is
obviously an area worthy of considerably more research especially
as cancer is predominantly a disease of the elderly.
CONCLUSIONS
Given the current state of knowledge, the Group would recom-
mend that:
1.Age, per se, should not be an exclusion factor for clinical
trials. Criteria such as performance status, creatinine clearance,
etc. (which may show correlation with age) should be used
instead.
2.Clinical trials directed specifically at the elderly should only
take place where there is clear evidence that the biology of the
target disease is different in the elderly (e.g. AML). (However,
it could be argued that inclusion should still be determined by
the biological parameters rather than age per se.)
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aiming to list inclusion criteria rather than exclusion criteria.
4. For trials where not all patients are entered into quality of life
and/or health economic studies, there should be separate
sections investigating these for the elderly patients who are
recruited.
5. Clinicians should not be encouraged to ‘pressurize’ elderly
patients into entering trials. Ideally, the proportion of elderly
patients offered trial entry should be similar to that for all
patients, although the number actively accepting may be lower.
6. It may be that, in future, clinical trials of palliative/terminal
care should be given a higher priority. This would be likely to
shift trial resources towards a more elderly population and may
spread trial benefit more evenly amongst the cancer patient
population.
7. There is a need for substantial further funded research into
problems associated with the entry of elderly patients into
trials. Specific areas of research should include:
a. Investigation of the reasons for the late presentation by
elderly patients
b. Identification of cases of late diagnosis in general practice
and strategies for improvement
c. Examination of GP attitudes towards cancer in the elderly
d. Detailed studies of temporal changes, and the underlying
reasons, in representation of older patients in clinical trials
e. Detailed studies of outcomes of cancer treatment in
relation to patient age, and temporal changes in these.
f. Clinical trials aimed at determining optimal treatments for
frail cancer patients, irrespective of age.
Such research may help to ensure that the distribution of ages of
patients entering trials more accurately reflects the age distribution
of patients who will receive the novel treatment if it enters into
routine procedure. (This is important not only for a survival end
point but also for quality of life and/or health economic measures.)
In the longer term, this should improve the treatment of cancer in
the elderly by ensuring that a larger population of elderly patients
are offered the most modern therapies.
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